These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29309486)

  • 41. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
    Tian R; Zhang G; Tang S; Guo J; Tan W
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
    Wallace DK; Kraker RT; Freedman SF; Crouch ER; Hutchinson AK; Bhatt AR; Rogers DL; Yang MB; Haider KM; VanderVeen DK; Siatkowski RM; Dean TW; Beck RW; Repka MX; Smith LE; Good WV; Hartnett ME; Kong L; Holmes JM;
    JAMA Ophthalmol; 2017 Jun; 135(6):654-656. PubMed ID: 28448664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Stahl A; Lepore D; Fielder A; Fleck B; Reynolds JD; Chiang MF; Li J; Liew M; Maier R; Zhu Q; Marlow N
    Lancet; 2019 Oct; 394(10208):1551-1559. PubMed ID: 31522845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
    Wallace DK; Kraker RT; Freedman SF; Crouch ER; Bhatt AR; Hartnett ME; Yang MB; Rogers DL; Hutchinson AK; VanderVeen DK; Haider KM; Siatkowski RM; Dean TW; Beck RW; Repka MX; Smith LE; Good WV; Kong L; Cotter SA; Holmes JM;
    JAMA Ophthalmol; 2020 Jun; 138(6):698-701. PubMed ID: 32324197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
    ; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
    JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
    Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
    VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
    Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
    Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
    Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
    BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
    Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
    Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
    Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry.
    Pfeil JM; Barth T; Lagrèze WA; Lorenz B; Hufendiek K; Liegl R; Breuss H; Bemme S; Aisenbrey S; Glitz B; Süsskind D; Gabel-Pfisterer A; Skevas C; Krohne TU; Kakkassery V; Bründer MC; Engelmann K; Guthoff R; Walter P; Choritz L; Stahl A;
    Ophthalmol Retina; 2024 Jun; 8(6):579-589. PubMed ID: 38104929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial.
    Fidler M; Fleck BW; Stahl A; Marlow N; Chastain JE; Li J; Lepore D; Reynolds JD; Chiang MF; Fielder AR;
    Transl Vis Sci Technol; 2020 Jul; 9(8):43. PubMed ID: 32855889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
    Crouch ER; Kraker RT; Wallace DK; Holmes JM; Repka MX; Collinge JE; Bremer DL; Gray ME; Smith HA; Steinkuller PG;
    JAMA Ophthalmol; 2020 Jan; 138(1):14-20. PubMed ID: 31697304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
    Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
    Dikci S; Ceylan OM; Demirel S; Yılmaz T
    Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP.
    Ekinci DY; Vural AD; Bayramoglu SE; Onur IU; Hergunsel GO
    Int Ophthalmol; 2019 Dec; 39(12):2697-2705. PubMed ID: 30830544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.